



# optibrium

## Introduction to P450 Metabolism

Innovative Lead Optimization and Candidate Selection by *in Silico*  
Synthesis and ADMET Prediction. December 3<sup>rd</sup> 2015

Matthew Segall, CEO, Optibrium Ltd.

© 2015 Optibrium Ltd.

Optibrium™, StarDrop™, Auto-Modeller™ and Glowing Molecule™ are trademarks of Optibrium Ltd.

Derek Nexus™ is a trademark of Lhasa Limited.

# Overview


---

- Cytochrome P450
- Predicting P450 Metabolism
  - ‘Electronic’ contributions
  - Accessibility - steric and orientation
  - Generating metabolite structures
- Site Lability
- Conclusions

# Cytochrome P450s


---

- Ubiquitous superfamily of haem-containing monooxygenase enzymes



# Cytochrome P450s

- Responsible for ~70-80% of drug metabolism, leading to:
  - Rapid clearance or low bioavailability
  - Potential for drug-drug interaction
  - Impact of P450 polymorphism
  - Bioactivation to form reactive/toxic metabolites
- Primary isoforms responsible for drug metabolism in human




# P450 Catalytic Cycle


- Insertion of oxygen into ligand

- Increase hydrophilicity
- Facilitate secondary metabolism
- Facilitate excretion

Product  
formation  
step



# Predicting P450 Metabolism



# Methods







---

Two primary factors determine the site of metabolism:

- **Electronic properties of substrate**
  - H abstraction – aliphatic oxidation, N-dealkylation, O-dealkylation
  - Direct oxidation – aromatic oxidation, epoxidation, N-oxidation, S-oxidation
  - Activation barrier to abstraction of H and direct oxidation
  - Independent of isoform
- **Orientation of substrate in active site**
  - Electrostatic interactions with between protein and substrate
  - Freedom to move
  - Steric accessibility
  - Dependent on isoform and substrate

# Electronic Effects

## Trends in Metabolism Correlate with Radical Stability

Radical	$\delta\Delta H_f$ (kcal/mol)	Reaction Type
	17.3	N-dealkylation
	19.6	benzylic hydroxylation
	26.6	O-dealkylation
	27.7	aliphatic hydroxylation
	28.6	aliphatic hydroxylation
	33	$\omega$ -hydroxylation




Increasing  
occurrence of  
metabolism



# Electronic Models for CYP Reactivity

- Semi-empirical QM methods used to calculate energies of substrate and reaction intermediates
- Brönsted relationship to generate activation energy
- Fragment considered in context of molecular environment
  - Not considered as a discrete uniform entity
  - Subtle longer range effects can be captured
  - Important when developing a lead series



$$\Delta H_A \propto \Delta H_R$$

# Electronic Models for CYP Reactivity

---

- Free energy relationships have been developed to predict activation energies for oxidation reactions
  - Hydrogen atom abstraction
  - Aromatic oxidation
  - S-oxidation
  - N-oxidation
  - Epoxidation
  - ....
- Models have been parameterized with:
  - Experimental data\*
  - *Ab initio* calculations<sup>†</sup>

\*Jones, Mysinger & Korzekwa, Drug Metab. Dispos., **30**(1) p. 7 (2002)

# Steric and Orientation Effects


- Binding within active site restricts the accessibility of sites to the active oxy-haem species
- Structure of ligand introduces steric hindrance
- Corrections to activation energy estimated with statistically trained model using 2D descriptors, including
  - Distances to charged functionalities, H-bond acceptors/donors, lipophilic groups
  - Distances to rings, flexible linkers, 'bulky' groups
- Trained and tested using high-quality regioselectivity data sets carefully curated from the literature

Isoform	Number of Molecules
3A4	305
2D6	202
2C9	193
1A2	201
2C19	184
2E1	105
2C8	106

# Validation

Independent test sets of 30% of data

## Site of Metabolism Prediction Performance



# Metabolite Structure Generation

- SMIRKS patterns used to generate metabolite structures, e.g.


Reaction	SMIRKS
Aliphatic hydroxylation	<chem>[C;X4:1][H:2]&gt;&gt;[C:1][O][H:2]</chem>
Aromatic hydroxylation	<chem>[c:1][H:2]&gt;&gt;[c:1][O][H:2]</chem>
N dealkylation	<chem>[#7:1][C:2]([H])&gt;&gt;[#7:1][H].[C:2]=[O]</chem>
S oxidation	<chem>[#16:1]&gt;&gt;[#16:1](=[O])</chem>

- Metabolites can be exported into a new data set for further analysis, e.g. activity, physicochemical properties, etc.
  - Output exact mass to aid metabolite ID experiments


# Example Regioselectivity Prediction

## Venlafaxine


CYP3A4




CYP2D6



# Site Lability



# P450 Metabolic Lability




- Oxidation of a site on the molecule is in competition with water formation (and deactivation of the P450 active site).
- Site lability is a measure of how easily a site is oxidised compared to water formation, governing the efficiency of product formation.




# P450 Metabolic Landscape

A



B



- This output indicates how **vulnerable** a molecule is to metabolism by CYP3A4, **if** it binds as a substrate
- Which compound is a better opportunity for optimisation?





# Composite Site Lability (CSL)

---

- The **Composite Site Lability** is a measure of the efficiency of metabolism of a molecule by CYP3A4
- CSL varies between 0.0 and 1.0
  - Lower values imply greater metabolic stability
- A **labile site** on a molecule may need modification to improve its stability
- Site lability is an important factor affecting rate of metabolism, but other factors are important
  - E.g. binding affinity, reduction rates (type I and type II binding)

# Example

## Clozapine vs Amoxapine



# Conclusions

---

- Models of P450 metabolism can accurately predict site of metabolism and metabolites
- Predicting sites of metabolism is useful but not sufficient for compound design
- QM approaches can be used to estimate lability on an absolute scale
  - With corrections for steric accessibility and orientation
  - Fragments considered in their molecular environment
- Acknowledgement
  - This research has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under the grant agreement no602156

